Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep 8;8(3):511.
doi: 10.3390/vaccines8030511.

A Zigzag but Upward Way to Develop an HIV-1 Vaccine

Ziyu Wen  1 , Caijun Sun  1   2
Affiliations
Review

A Zigzag but Upward Way to Develop an HIV-1 Vaccine

Ziyu Wen et al. Vaccines (Basel). .

Abstract

After decades of its epidemic, the human immunodeficiency virus type 1 (HIV-1) is still rampant worldwide. An effective vaccine is considered to be the ultimate strategy to control and prevent the spread of HIV-1. To date, hundreds of clinical trials for HIV-1 vaccines have been tested. However, there is no HIV-1 vaccine available yet, mostly because the immune correlates of protection against HIV-1 infection are not fully understood. Currently, a variety of recombinant viruses-vectored HIV-1 vaccine candidates are extensively studied as promising strategies to elicit the appropriate immune response to control HIV-1 infection. In this review, we summarize the current findings on the immunological parameters to predict the protective efficacy of HIV-1 vaccines, and highlight the latest advances on HIV-1 vaccines based on viral vectors.

Keywords: HIV-1 vaccine; immune correlation; protection; viral vector.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The inferred immune correlates of protection for HIV-1 vaccines.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Suntharasamai P., Martin M., Vanichseni S., van Griensven F., Mock P.A., Pitisuttithum P., Tappero J.W., Sangkum U., Kitayaporn D., Gurwith M., et al. Factors associated with incarceration and incident human immunodeficiency virus (HIV) infection among injection drug users participating in an HIV vaccine trial in Bangkok, Thailand, 1999-2003. Addiction. 2009;104:235–242. doi: 10.1111/j.1360-0443.2008.02436.x. - DOI - PubMed
    1. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., Gilbert P.B., Lama J.R., Marmor M., Del Rio C., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372:1881–1893. doi: 10.1016/S0140-6736(08)61591-3. - DOI - PMC - PubMed
    1. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., Premsri N., Namwat C., de Souza M., Adams E., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009;361:2209–2220. doi: 10.1056/NEJMoa0908492. - DOI - PubMed
    1. Gilbert P.B., Berger J.O., Stablein D., Becker S., Essex M., Hammer S.M., Kim J.H., Degruttola V.G. Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: A case study for statistical issues in efficacy trials. J. Infect. Dis. 2011;203:969–975. doi: 10.1093/infdis/jiq152. - DOI - PMC - PubMed
    1. UNAIDS. HVTN 702 Clinical Trial of an HIV Vaccine Stopped. [(accessed on 4 February 2020)]; Available online: https://www.unaids.org/en/resources/presscentre/pressreleaseandstatement....

LinkOut - more resources